scispace - formally typeset
G

Guilin Peng

Researcher at Guangzhou Medical University

Publications -  46
Citations -  668

Guilin Peng is an academic researcher from Guangzhou Medical University. The author has contributed to research in topics: Cancer & Lung cancer. The author has an hindex of 14, co-authored 44 publications receiving 523 citations.

Papers
More filters
Journal ArticleDOI

Prognostic Significance of Programmed Cell Death 1 (PD-1) or PD-1 Ligand 1 (PD-L1) Expression in Epithelial-Originated Cancer: A Meta-Analysis

TL;DR: PD-L1 or PD-1 expression status is a significant prognostic factor in epithelial-originated malignancies and all subgroups showed consistent trends toward unfavorable prognoses of patients with positive PD-L 1 expression, regardless of antibodies and evaluation cutoffs.
Journal ArticleDOI

Analysis of feasibility and safety of complete video-assisted thoracoscopic resection of anatomic pulmonary segments under non-intubated anesthesia.

TL;DR: Complete video-assisted throacoscopic segmentectomy under anesthesia without endotracheal intubation is a safe and feasible technique that can be used to treat a selected group of IA patients with primary lung cancer, lung metastases and benign diseases.
Journal ArticleDOI

MicroRNA-186 suppresses cell proliferation and metastasis through targeting MAP3K2 in non-small cell lung cancer.

TL;DR: The data indicated that miR-186 regulates lung cancer growth and metastasis through suppressing MAP3K2 expression, at least partly, and may represent a new and useful potential clinical treatment and diagnosis target for NSCLC.
Journal ArticleDOI

Non-intubated combined with video-assisted thoracoscopic in carinal reconstruction

TL;DR: Non-intubated complete VATS carinal reconstruction in a patient with adenoid cystic carcinoma of the lower trachea makes the surgery easier, especially during the anastomosis of stumps.
Journal ArticleDOI

Evaluation of the efficacy and safety of anti-PD-1 and anti-PD-L1 antibody in the treatment of non-small cell lung cancer (NSCLC): a meta-analysis.

TL;DR: Anti-PD-1 and anti PD-L1 antibodies showed objective responses in approximately one fourth NSCLC patients with a tolerable adverse-effect profile, and median-dose (3 mg/kg) might be a preferential dosage of anti- PD-1 agents.